Drug Type Fluorescent Peptide |
Synonyms Chlorotoxin-indocyanine-green-conjugate, Tozuleristide (USAN/INN), Tumour paint + [6] |
Target |
Action modulators |
Mechanism chloride channel modulators(Chloride channel modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dysplasia | Phase 2 | United States | 17 Apr 2024 | |
Squamous cell carcinoma of the oral cavity | Phase 2 | United States | 17 Apr 2024 | |
Lung Cancer | Preclinical | United States | 18 Jun 2024 | |
Prostatic Cancer | Preclinical | United States | 18 Jun 2024 | |
Childhood Central Nervous System Neoplasm | Preclinical | United States | 26 Nov 2018 | |
Soft Tissue Sarcoma | Preclinical | United States | 01 Sep 2015 | |
Breast Cancer | Preclinical | United States | 01 Jul 2015 | |
Glioma | Preclinical | Australia | 01 Oct 2014 | |
Glioma | Preclinical | United States | 01 Oct 2014 | |
Skin Neoplasms | Preclinical | Australia | 01 Dec 2013 |
Phase 2/3 | 118 | Canvas System (Arm 1 (no Tozuleristide)) | offwgvzcab(nqusmxzdql) = usvreotngm rsbsucwlew (uvlxdmrrkb, zfxrxkarsu - aeeywhzres) View more | - | 27 Jun 2024 | ||
Canvas System+tozuleristide (Arm 2 (Tozuleristide Treated)) | offwgvzcab(nqusmxzdql) = funpdkusgi rsbsucwlew (uvlxdmrrkb, bjdfnqvmex - thnlfdqabk) View more | ||||||
Phase 1 | 17 | (sweowcrtlz) = no reported adverse events were considered related to tozuleristide dclrqlvlnt (cvlshthlot ) View more | Positive | 01 Oct 2019 | |||
Not Applicable | 40 | pqcetguikb(qzbmtwtndn) = ztxmiwwcvx gavrpisxyd (mfkqggiist ) | - | 05 Dec 2016 |